West Virginia University Healthcare — Biomedical Watch V2

Essais liés7clinical trials

VilleMorgantownlocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07198074

Ouvrir le site du centre

Essais cliniques associés

7

Molécule	Indication / population	Phase	NCT	Titre	Statut
Biospecimen Collection	Cancer	Phase 2	NCT06770582	Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT07097142	Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study	RECRUITING
Bevacizumab	Cancer	Phase 3	NCT07198074	Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT05256225	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma	RECRUITING
Biospecimen Collection	Cancer	Phase 3	NCT04267848	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	RECRUITING
Biopsy Procedure	Cancer	Phase 2	NCT06126276	Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)	RECRUITING